文献速递心血管MR

核纤层蛋白(LMNA)心脏病的心血管磁共振表型

The Cardiovascular Magnetic Resonance Phenotype of Lamin Heart Disease.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-05-14

这项前瞻性多中心研究纳入187人,比较LMNA携带者(射血分数保留或降低)、扩张型心肌病野生型患者与健康志愿者的心血管磁共振表型,发现LMNA携带者即使收缩功能保留也存在T2延长、细胞外容积增高、心肌应变受损和肌钙蛋白升高,且局灶纤维化和应变指标与主要不良心血管事件相关。

要点

  • LMNA携带者即使左室射血分数≥55%,仍可见T2延长、细胞外容积增高和心肌应变受损。
  • LMNA携带者较DCMwt患者肌钙蛋白和C反应蛋白更高,提示亚临床心肌损伤和炎症。
  • 整体晚期钆增强每增加1%,MACE的HR为1.15;Procrustes轨迹尺寸每降低1%,HR为1.01。

核心结论

  • LMNA携带者收缩功能保留时的心血管磁共振表型包括T2延长、血清肌钙蛋白升高、细胞外容积增高和应变受损;磁共振衍生的局灶纤维化和应变生物标志物具有预后价值。

研究设计与样本

  • 前瞻性多中心研究,纳入187人,分4组:Lamin+EF组29例(38±14岁)、Lamin-EF组38例(45±17岁)、DCMwt组73例(45±15岁)、健康志愿者47例(44±20岁);采用体模校准的心血管磁共振 cine、晚期钆增强和多参数映射,并用广义Procrustes分析重建左室形状。

关键影像表现/征象

  • 与健康志愿者相比,Lamin+EF组体模归一化T2延长10(95%CI:2-20),细胞外容积增高3%(95%CI:1%-6%),心肌动力学更差。
  • 与DCMwt组相比,Lamin+EF组心肌动力学更好但体模归一化T2更高(20 vs 12;P=0.010),血清肌钙蛋白更高(27 ng/L vs 5 ng/L;P<0.001),C反应蛋白更高(8 mg/L vs 3 mg/L;P=0.021)。
  • 与DCMwt组相比,Lamin-EF组心肌动力学相似,但血清肌钙蛋白更高(13 ng/L vs 5 ng/L;P<0.001),N末端B型利钠肽原更高(668 pg/mL vs 228 pg/mL;P=0.025),体模归一化T2延长16(95%CI:1-31),细胞外容积增高5%(95%CI:1%-9%)。

诊断标准与关键数值

  • 在LMNA携带者中,整体晚期钆增强每增加1%,MACE的HR为1.15(95%CI:1.02-1.30,P≤0.025)。
  • 在LMNA携带者中,Procrustes轨迹尺寸每降低1%,MACE的HR为1.01(95%CI:1.01-1.02,P≤0.025)。
  • 4年随访期间,LMNA携带者中21%发生MACE,DCMwt组中6%发生MACE(P<0.001)。

临床应用与阅片要点

  • 对LMNA携带者,即使左室射血分数保留,也应关注T2、细胞外容积和应变等亚临床指标。
  • 整体晚期钆增强和Procrustes轨迹尺寸可能有助于LMNA携带者的MACE风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Lamin (LMNA) heart disease is a lethal form of dilated cardiomyopathy (DCM).

OBJECTIVES: The authors explored its cardiovascular magnetic resonance (CMR) phenotype to discover prognostically useful and subclinical biomarkers.

METHODS: This prospective multicenter study recruited 4 groups: LMNA carriers with left ventricular ejection fraction ≥55% (Lamin+EF), LMNA carriers with left ventricular ejection fraction <50% (Lamin-EF), individuals with DCM with wild-type LMNA (DCMwt), and healthy volunteers. Phantom-calibrated CMR comprising cines, late gadolinium enhancement, and multiparametric mapping was undertaken. Left ventricular shapes were reconstructed using generalized Procrustes analysis. Serum biomarkers were collected at the time of CMR. Using a major adverse cardiovascular events (MACE) outcome of cardiovascular death, life-threatening ventricular tachyarrhythmia, heart transplantation, or atrioventricular block requiring pacing, we explored the prognostic value of CMR metrics using Cox regression.

RESULTS: A total of 187 individuals were recruited (50% male): 29 with Lamin+EF (38 ± 14 years), 38 with Lamin-EF (45 ± 17 years), 73 with DCMwt (45 ± 15 years), and 47 healthy volunteers (44 ± 20 years). Compared to HVs, Lamin+EF had longer phantom-normalized T2 by 10 (95% CI: 2-20), higher ECV by 3% (95% CI: 1%-6%), and worse myocardial dynamics. Compared with DCMwt participants, Lamin+EF participants had better myocardial dynamics, higher phantom-normalized T2 (20 vs 12; P = 0.010), higher serum troponin (27 ng/L vs 5 ng/L; P < 0.001), and higher C-reactive protein (8 mg/L vs 3 mg/L; P = 0.021). Lamin-EF participants had similar myocardial dynamics but higher serum troponin (13 ng/L vs 5 ng/L; P < 0.001), higher N-terminal pro-B-type natriuretic peptide (668 pg/mL vs 228 pg/mL; P = 0.025), longer phantom-normalized T2 by 16 (95% CI: 1-31), and higher extracellular volume by 5% (95% CI: 1%-9%) than DCMwt participants. Over 4 years, 21% of lamin and 6% of DCMwt participants experienced MACE (P < 0.001). In lamin participants, each 1% increase in global late gadolinium enhancement and each 1% decrease in Procrustes trajectory sizes associated with HRs for MACE of 1.15 (95% CI: 1.02-1.30) and 1.01 (95% CI: 1.01-1.02), respectively (both P ≤ 0.025).

CONCLUSIONS: The CMR phenotype of LMNA carriers with preserved left ventricular systolic function consists of longer T2, higher serum troponin levels, higher extracellular volume, and impaired strain. CMR-derived focal fibrosis and strain biomarkers are prognostic, and future studies should explore their added clinical utility beyond the currently available MACE risk prediction tools. (The Deep Phenotype of Lamin A/C Cardiomyopathy; NCT03860454).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Topriceanu CC, Al-Farih M, Joy G, et al. The Cardiovascular Magnetic Resonance Phenotype of Lamin Heart Disease. JACC Cardiovasc Imaging. 2025. PMID: 40372342. doi:10.1016/j.jcmg.2025.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。